| First Author | Saito M | Year | 2022 |
| Journal | J Invest Dermatol | Volume | 142 |
| Issue | 4 | Pages | 1040-1049.e8 |
| PubMed ID | 34592332 | Mgi Jnum | J:324601 |
| Mgi Id | MGI:7280978 | Doi | 10.1016/j.jid.2021.09.007 |
| Citation | Saito M, et al. (2022) PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis. J Invest Dermatol 142(4):1040-1049.e8 |
| abstractText | Squamous cell carcinomas (SCCs) are one of the most frequent solid cancer types in humans and are derived from stratified epithelial cells found in various organs. SCCs derived from various organs share common important properties, including genomic abnormalities in the tumor suppressor gene p53. There is a carcinogen-induced mouse model of SCC that produces benign papilloma, some of which progress to advanced carcinoma and metastatic SCCs. These SCCs undergo key genetic alterations that are conserved between humans and mice, including alterations in the genomic p53 sequence, and are therefore an ideal system to study the mechanisms of SCC tumorigenesis. Using this SCC model, we show that the PHLDA3 gene, a p53-target gene encoding a protein kinase B repressor, is involved in the suppression of benign and metastatic tumor development. Loss of PHLDA3 induces an epithelialmesenchymal transition and can complement p53 loss in the formation of metastatic tumors. We also show that in human patients with SCC, low PHLDA3 expression is associated with a poorer prognosis. Collectively, this study identifies PHLDA3 as an important downstream molecule of p53 involved in SCC development and progression. |
